Replies to post #180 on Seagen Inc (SGEN)

[surf1944]

9:05AM Seattle Genetics and Agensys, an Affiliate of Astellas (ALPMY), announce co-development of an additional antibody-drug conjugate under existing collaboration (SGEN) 30.86 : Co announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate under the companies' existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the FDA for a phase 1 trial of ASG-15ME.